US health officials are looking into concerns that Moderna Inc’s (MRNA.O) COVID-19 vaccination may be related to a higher risk of a rare cardiac ailment in young adults than previously assumed.
According to the article, the study focused on Canadian data that indicated a higher risk from the shot than the Pfizer-BioNTech vaccine, especially in men under the age of 30.
According to a source referenced in the Washington Post piece, the regulators are still too early to form a conclusion, and more investigation is needed before any recommendations are made.
“While we won’t comment on internal meetings or discussions, we can say that FDA is absolutely committed to reviewing data as it becomes available to us,” the U.S. Food and Drug Administration said. Moderna did not immediately respond to Reuters’ requests for comment.
The possible review comes just two days after US health officials announced that COVID-19 vaccine booster doses will be available to Americans beginning September 20 due to concerns that initial vaccinations may provide insufficient protection in the face of rising infections caused by the Delta variant.
In June, health officials added a warning to the literature that accompanies mRNA vaccines made by Moderna and Pfizer (PFE.N) to highlight an uncommon risk of cardiac inflammation that affects mostly young boys.
During that month, data from a government agency’s safety monitoring system revealed that the rate of heart inflammation in 12-to 39-year-olds was 12.6 instances per million.
*This article was written by Gerald Gekara for Uzalendo News. Email: uzalendonews24@gmail.com to submit your story.
